Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
zipalertinib
product2 mentionslast seen Oct 2, 2026
An orally available small molecule designed to target activating mutations in EGFR, specifically inhibiting EGFR variants with exon 20 insertion mutations.
Relationships 9
- Taiho Oncology, Inc.developszipalertinib99% confidence2 sources
- Cullinan Therapeutics, Inc.developszipalertinib99% confidence2 sources
- Taiho Pharmaceutical Co., Ltd.developszipalertinib99% confidence1 source
- zipalertinibapplies tonon-small cell lung cancer99% confidence1 source
- zipalertinibapplies tonon-small cell lung cancer treatment95% confidence1 source
- zipalertinibconforms toFDA Real-Time Oncology Review Program90% confidence1 source
- zipalertinibdepends onEGFR inhibitor85% confidence1 source
- zipalertinibdepends oncisplatin-based chemotherapy85% confidence1 source
- REZILIENT3 Phase 3 trialciteszipalertinib80% confidence1 source
Relationship
Cullinan Therapeutics, Inc.developszipalertinib
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 1, 2026Cullinan Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc.
- filingSEC EDGARSep 14, 2026Cullinan Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.